UK

#ABPI #Marketing approval authorisation #MHRA #Regulatory #UK

New UK authorisation policy draws on international drug approvals

The UK Medicines and Healthcare products Regulatory Agency’s (MHRA) new International Recognition procedure (IRP) will allow it to draw on the expertise of regulators in other countries when authorising medicines. The MHRA will retain ultimate authority to accept or reject applications submitted under the IRP, but it is hoped that… Read More

#News #Regulatory

Innovation Centre, London
#Biotech hubs #Lab space #Life sciences #London #UK

Lab space in London helps meet UK’s ‘severe shortage’

Kadans Science Partner has acquired space within the Knowledge Quarter, London to deliver laboratory accommodation to the UK life sciences market. The Knowledge Quarter Kings Cross boasts a range of academic, research, and scientific organisations from The Francis Crick Institute and University College London (UCL) to the Wellcome Trust, Google,… Read More

#Business & Investment #News

Downing Street, London, UK
#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

Changes to UK Statutory Scheme go ahead despite pharma criticism

The UK government has published new terms for the Statutory Scheme for branded medicines, which controls the prices of medicines paid by the NHS. The announcement follows the agreement in mid-November of a new Voluntary Scheme for Pricing, Access and Growth (VPAG), a negotiated alternative scheme which companies can opt… Read More

#Business & Investment #News #Trending News

Glasgow Health Innovation Hub
#Biotech hubs #Expansion #Life sciences #UK #University of Glasgow

Glasgow innovation hub sets the scene for new life sciences cluster

The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, have announced plans to construct a new Health Innovation Hub in Govan in Glasgow. It is hope that the new centre, which is due for completion in summer 2025, will set the stage for… Read More

#News

#Drug discovery #Lab space #UK #UK economy

Lack of lab space hindering growth in the UK, report finds  

The UK must build more laboratory space if it is to meet its global ambitions of becoming a scientific leader, property firms and estate agencies have argued.  A report published by British Land and Savills states that there is a severe shortage of laboratory space to meet… Read More

#News

Carbon neutral concept
#Climate change #Drug research #Life sciences #Sustainability #UK

Francis Crick aims for net zero by 2040  

The Francis Crick Institute has announced goals to reduce its operational carbon emissions by 50% by 2030, along with a longer-term target to be net zero carbon by 2040.  The biomedical discovery centre, which is based in London, published a new sustainability strategy that it says has… Read More

#News

UK
#BioIndustry Association #European Federation of Pharmaceutical Industries and Associations #Rare disease #UK

UK lags behind on access to treatments for rare diseases

The UK lags comparable countries, including France and Germany, on the degree of availability of treatments for rare diseases, according to a new report. The report by the BIA and consultancy firm PwC has highlighted the progress that has been made in improving access to rare… Read More

#News

Medical professional examining mammogram
#Breast cancer #Drug repurposing #Hormone therapy #MHRA #Oncology #UK

UK women to benefit from drug to prevent breast cancer

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised a new indication for anastrozole, to prevent breast cancer in post-menopausal women at moderate or high risk of developing the disease. The hormone treatment was already authorised for use in the treatment of breast cancer… Read More

#News #Trending News

Non-small cell lung cancer
#Lung cancer #MHRA #Mirati Therapeutics #Non-small cell lung cancer (NSCLC) #Oncology #UK

MHRA approves drug for lung cancer with limited therapy options

The UK regulator has approved a new treatment for non-small cell lung cancer (NSCLC) in adults that has a mutation and produces a rare protein called KRAS G12C. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Krazati (adagrasib) to treat patients whose disease is advanced or has spread… Read More

#News #Regulatory

Hematopoietic cells
#Cancer research #Clinical trial #Gene therapy #MHRA #Paediatrics #Phase I trial #Stem cells #UK

First gene therapy trial for Hunter syndrome opens in Manchester, UK

UK regulatory authorities have approved the first trial of a gene therapy for young children with Hunter syndrome. The UK Medicines and Healthcare Products Regulatory Agency (MHRA), Research Ethics Committee (REC), and Health Research Authority (HRA) have all approved the clinical trial application that was submitted by The University of… Read More

#Editor's Choice #News #Regulatory

#Drug development #Drug discovery #Life science #Life sciences #Market reporting #TechBio #UK

‘Life Sciences Future50’ shines light on UK innovation

PwC has published a new report on the UK life sciences industry ‘The Life Sciences Future50’, highlighting companies that illustrate world-class science and innovation, including 32 in the therapeutics space. According to the report, the life science industry represents a £43.4 ($52.7) billion annual contribution to GVA and supports 646,000… Read More

#News #Trending News #Trends & Analysis

Blood cancer
#Bispecific Antibodies #Cancer research #Haematology #MHRA #Oncology #UK

New UK therapy option for hard-to-treat lymphoma

The MHRA has granted conditional marketing authorisation for Tepkinly (epcoritamab) as a bispecific treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The conditional marketing authorisation for Great Britain is based on the single-arm Phase I/II EPCORE NHL-1 trial… Read More

#News #Regulatory

#Artificial intelligence (AI) #BioIndustry Association #Machine learning #TechBio #UK

Five UK TechBio companies driving the AI revolution

The UK TechBio sector is thriving, according to a new report, with a growing number of companies pioneering ground-breaking products and services. A BioIndustry Association (BIA) report lists the widespread adoption of artificial intelligence (AI) and machine learning (ML), the advancement of gene editing technologies, the power of engineering biology,… Read More

#News #Trends & Analysis

Cryoport & CGT Catapult facility
#Cell and gene therapy #CGT Catapult #Cryoport #Partnership #Supply chain #UK

New CGT supply chain logistics centre for Stevenage, UK, bio hub

Cryoport and the Cell and Gene Therapy Catapult have entered into a new strategic partnership to support the advancement of cell and gene therapies. As part of the deal, Cryoport will establish a Good Manufacturing Practice (GMP)-compliant global supply chain logistics centre in the UK at… Read More

#News

MHRA
#Clinical Trial Authorisation #Clinical trial design #Clinical trials #MHRA #Phase III trial #UK

UK regulator cuts late-stage clinical trial approval time to two weeks

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed plans to reduce the time taken to approve the lowest-risk clinical trials by more than 50%. According to the plans, initial applications for the lowest-risk Phase III and IV trials will be processed by the MHRA within 14 days… Read More

#News #Regulatory

UK
#Drug development #Drug discovery #England #Golden Triangle #Northern Ireland #Scotland #UK

Where is the drug discovery expertise happening in the UK?

Listen to this article on the DDW Podcast: The United Kingdom has established itself as a hub for drug discovery expertise worldwide. Here, DDW’s Megan Thomas highlights the research taking place and where this is happening. The Golden Triangle Though the UK is constantly expanding in terms of where drug discovery… Read More

#Exclusive Content #Market Reports